Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet;Papel del polimorfismo G1359A del gen del receptor endocanabinoide tipo 1 (CNR1) en la perdida de peso y adipocitoquinas tras una dieta hipocalórica

Nutricion Hospitalaria

Volumn 26, Issue 2, 2011, Pages 317-322

  de Luis, D A ^a   Gonzalez Sagrado M ^a   Aller, R ^a   Conde, R ^a   Izaola, O ^a   de la Fuente, B ^a   Primo, D ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipocytokines; Cannabinoid receptor gene; Hypocaloric diet; Obesity

Indexed keywords

ADIPOCYTOKINE; CANNABINOID 1 RECEPTOR; INTERLEUKIN 6; LEPTIN; RESISTIN;

ADULT; ALLELE; ARTICLE; BLOOD; CALORIC RESTRICTION; CALORIMETRY; DIET THERAPY; EXERCISE; FEEDING BEHAVIOR; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MEDITERRANEAN DIET; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

ADIPOKINES; ADULT; ALLELES; CALORIC RESTRICTION; CALORIMETRY, INDIRECT; DIET, MEDITERRANEAN; EXERCISE; FEMALE; FOOD HABITS; GENOTYPE; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1; RESISTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WEIGHT LOSS;

EID: 79955541546     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2011.26.2.4921     Document Type: Article

References (32)

1. De Luis DA, Aller R, Izaola O, González Sagrado, Conde R, Perez Castrillon JL. Effects of lifestyle modification on adipocytokine levels in obese patients. Eur Rev Med Pharmacol Sci 2008; 12: 33-39.
2. Ameri A. The effects of cannabinnoids on the brain. Prog Neurobiol 1999; 58: 315-348.
3. Brown SM, Warger-Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 2002; 1576: 255-264.
4. Fride E. Endocannabinoids in the central nervous system an overview. Prostaglandins Leukot Essent Fatty acids 2002; 66: 221-233.
5. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Ann Rev Pharmacol Toxicol 1998: 38: 179-200.
6. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P,. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
7. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13: 321-323.
8. Duart MJ, Arroyo CO, Moreno JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
9. Duart MJ, Arroyo CO, Moreno JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
10. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher Df. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
11. Pfutzner A, Langefeld M, Kunt T, Lobig M. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin lab 2003; 49: 571-576.
12. Meier U, Gressner M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.
13. Suominen P. evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 2004; 50: 219-221.
14. Lubrano V, Cocci F, Battaglia D, Papa A. Usefulness of high-sensitivity IL6 measurment for clinical characterization of patients with coronary artery disease. J Clin Lab Anal 2005; 19: 110-114.
15. Khan SS, Smith MS, Reda D, Suffredini AF, Mc Coy JP. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufactures. Cytometry B Clin Cytom 2004; 61: 35-39.
16. Feurer ID, Mullen JL. Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1986; 1: 43-49.
17. Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. Clin Res 1993; 41: 53.
18. Mataix J, Mañas M. Tablas de composición de alimentos españoles. Ed: University of Granada, 2003.
19. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin. Regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
20. Engeli S, Jana B, Mareike F, Kerstin G, Jürgen J, Sandor B. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
21. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M. Association between cannabinoid type 1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes 2007; 31: 908-912.
22. Aberle J, Flitsch J, Alessia N, Mann O, Busch P, Peitsmeier P, Ulrich F. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Molecular Genetics and Metabolism 2008: 95: 188-191.
23. Jaeger J, Mattevi V, Callegari-Jacques SD, Hutz MH. Cannabinoid type 1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Disease Markers 2008; 25: 67-74.
24. Russo P, Strazzullo P, Cappuccio F, Tregouet D, Lauria F, Loguercio M, Barba G et al. Genetic variations at the endocannabinoid type 1 receptor gene (CRN1) are associated with obesity phenotypes in Men. J Clin endo and Metan 2007; 92: 2382-2389.
25. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the endocannabinoid receptor gene is associated with abdominal adiposity in obese men. Endocr 2007: 31: 138-141.
26. Benzinou M, Chevre JC, Ward K, Lecoeur C, Dina C, Lobbens S et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index European population. Human Molecualr Genetics 2008; 17: 1916-1921.
27. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A. The CB1 receptor antagonist rimonabant reverses the diet induced obesity phenotype through the regulation of lipólisis and energy balance. FASEB J 2005; 19: 1567-1569.
28. Bensaid M, Gary Bobo M, Esclangron A, Maffrand JP, Le Fut G, Oury DOnat F. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp 30 mRNA expresión in adipose tissue of obese fa/fa rats and in cultures adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
29. Poirier B, Bidoauard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obes, Metab 2005; 7: 65-72.
30. Despres JP, Golay A, Sjostrom L. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipemia. NEJM 2005; 353: 2121-2130.
31. Thanos PK, Ramalhete RC, Michelides M, Piyis YK, Wang GJ, Volkow ND. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse 2008; 62: 637-642.
32. Malcher Lopes R, Di S, Marcheselli VS, Weng FJ, Stuart CT, Bazan NG, Tasker JG. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006; 26: 6643-6650.